(ADIL) Adial Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00688A1060
ADIL: Therapeutics, Addiction, Disorders, Antagonist, Pain, Medications
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutics for addiction and related disorders. Its lead product, AD04, a serotonin-3 receptor antagonist, is currently in Phase 3 clinical trials for the treatment of alcohol use disorder. The company is also exploring drug candidates for non-opioid pain management and other undisclosed indications. Founded in 2010 and headquartered in Glen Allen, Virginia, Adial Pharmaceuticals focuses on addressing unmet medical needs in addiction and pain management.
As of the latest data, Adial Pharmaceuticals has a market capitalization of $4.86M USD, with a price-to-book ratio of 1.19. The stock is traded on the NASDAQ exchange under the ticker symbol ADIL and is classified under the Pharmaceuticals sub-industry. The companys stock has shown an average 20-day trading volume of 96,304 shares, with a last price of $0.63. Key technical indicators include a 20-day SMA of $0.77, a 50-day SMA of $0.88, and a 200-day SMA of $1.03, signaling a recent downtrend. The ATR of $0.08 reflects moderate volatility in the stocks price action.
3-Month Forecast Based on the provided data, Adial Pharmaceuticals stock is expected to remain under pressure in the near term. The declining trend in SMA indicators (20-day: $0.77, 50-day: $0.88, 200-day: $1.03) suggests limited upward momentum. The stocks low average volume (96,304 shares over 20 days) and narrow ATR ($0.08) may restrict significant price movements. From a fundamental perspective, the companys small market capitalization ($4.86M USD) and lack of earnings (P/E: 0.00) highlight the high-risk nature of the investment. While AD04s Phase 3 trials for alcohol use disorder represent a potential catalyst, the stock is likely to remain volatile and sensitive to clinical updates or broader market conditions. Investors should approach with caution, considering the companys early-stage profile and limited financial resources.Additional Sources for ADIL Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ADIL Stock Overview
Market Cap in USD | 5m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2018-07-30 |
ADIL Stock Ratings
Growth 5y | -91.9% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength Industry | -60.5 |
Analysts | 4.33/5 |
Fair Price Momentum | 0.34 USD |
Fair Price DCF | - |
ADIL Dividends
No Dividends PaidADIL Growth Ratios
Growth Correlation 3m | -94.7% |
Growth Correlation 12m | -79.2% |
Growth Correlation 5y | -85.6% |
CAGR 5y | -53.89% |
CAGR/Max DD 5y | -0.54 |
Sharpe Ratio 12m | -0.15 |
Alpha | -62.09 |
Beta | -0.34 |
Volatility | 132.59% |
Current Volume | 99.4k |
Average Volume 20d | 91.6k |
As of March 15, 2025, the stock is trading at USD 0.69 with a total of 99,352 shares traded.
Over the past week, the price has changed by -7.47%, over one month by -6.38%, over three months by -36.63% and over the past year by -60.12%.
No, based on ValueRay Analyses, Adial Pharmaceuticals (NASDAQ:ADIL) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -91.93 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ADIL as of March 2025 is 0.34. This means that ADIL is currently overvalued and has a potential downside of -50.72%.
Adial Pharmaceuticals has received a consensus analysts rating of 4.33. Therefor, it is recommend to buy ADIL.
- Strong Buy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ADIL Adial Pharmaceuticals will be worth about 0.4 in March 2026. The stock is currently trading at 0.69. This means that the stock has a potential downside of -46.38%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 7.5 | 987% |
Analysts Target Price | 7.5 | 987% |
ValueRay Target Price | 0.4 | -46.4% |